**Review**

**GIRK Channels as Candidate Targets for the Treatment of Substance Use Disorders**

Hiroko Kotajima-Murakami, Soichiro Ide and Kazutaka Ikeda

Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan

* Correspondence: ikeda-kz@igakuken.or.jp; Tel.: +81-3-6834-2379

**Abstract:** Substance use disorders (SUDs) are chronic, lifelong disorders that have serious consequences. Repeated substance use alters brain function. G-protein-activated inwardly rectifying potassium (GIRK) channels are expressed widely in the brain, including the reward system, and regulate neuronal excitability. Functional GIRK channels are identified as heterotetramers of GIRK subunits (GIRK1–4). The GIRK1, GIRK2, and GIRK3 subunits are mainly expressed in rodent brain regions, and various addictive substances act on the brain through GIRK channels. Studies with animals (knockout and missense mutation animals) and humans have demonstrated the involvement of GIRK channels in the effects of addictive substances. Additionally, GIRK channel blockers affect behavioral responses to addictive substances. Thus, GIRK channels play a key role in SUDs, and GIRK channel modulators may be candidate medications. Ifenprodil is a GIRK channel blocker that does not have serious side effects. Two clinical trials were conducted to investigate the effects of ifenprodil in patients with alcohol or methamphetamine use disorder. Although the number of participants was relatively low, evidence of its safety and efficacy was found. The present review discusses the potential of GIRK channel modulators as possible medications for addiction. Therapeutic agents that target GIRK channels may be promising for the treatment of SUDs.

**Keywords:** GIRK channels; substance use disorder; ifenprodil; alcohol; methamphetamine; clinical trials

1. **Introduction**

Substance use disorders (SUDs) are characterized by compulsive drug use despite clinically significant distress and other negative consequences in life. Substance use disorders alter how the brain and body respond to addictive substances, and patients with SUDs suffer from an inability to quit addictive substances. Addictive substances comprise natural, semi-synthetic, and synthetic substances, such as amphetamine/methamphetamine, cocaine, opioids, cannabinoids, alcohol, hypnotics/anxiolytics, inhalants, nicotine, and caffeine. Addictive-substance misuse and problems that are associated with SUDs have been a serious societal concern worldwide. In 2022, the United Nations Office on Drugs and Crime reported on opioid-related overdose deaths in North America and Canada, the distribution of quantities of heroin and morphine seized in the Balkan route (the Islamic Republic of Iran, half of Transcaucasia, and South Eastern Europe), expansion of methamphetamine production in Afghanistan, distribution of quantities of cannabis resin seized, and trafficking in North Africa, Western and Central Europe, and South-West Asia [1]. However, research on pharmacotherapies for SUDs is still in an incipient stage. To develop new therapeutic agents, we need to focus on the mechanisms that contribute to SUDs. The present review focuses on G-protein-activated inwardly rectifying potassium (GIRK) channels. GIRK channels are expressed in the central nervous system, including brain regions that are related to reward and regulate neuronal excitability. Here, we highlight the involvement of GIRK channels in SUDs and describe the relevance of GIRK channels as potential treatment targets for patients with SUDs.
2. Fundamental Function of GIRK Channels and Response to Addictive Substances

GIRK channels are encoded by the \( Kcnj \) gene and assembled in homotetrameric or heterotetrameric units comprising four subunits: GIRK1 (\( Kcnj3 \)), GIRK2 (\( Kcnj6 \)), GIRK3 (\( Kcnj9 \)), and GIRK4 (\( Kcnj5 \)) [2–4]. Each GIRK subunit possesses two transmembrane domains, TM1 and TM2, that flank a hydrophobic pore domain and intracellular N- and C-terminal domains [4]. GIRK1-3-containing channels are widely expressed in the rodent brain, including the cerebral cortex, amygdala, hippocampus, thalamus, ventral tegmental area (VTA), locus coeruleus, and cerebellum. GIRK channels are expressed in the brain’s reward system [5,6]. The expression of GIRK4 subunits is found mainly in the heart and limited to only a few brain regions, such as the neocortex, insular cortex, cerebellar cortex, hypothalamus, thalamus, and brainstem [7,8]. Three primary GIRK channel subunits in the brain form heteromeric channels: GIRK1/GIRK2, GIRK1/GIRK3, and GIRK2/GIRK3 [4] (Figure 1A).

**Figure 1.** GIRK channel subunits in the brain and signal transduction of addictive substances through GIRK channels. Three types of GIRK subunits are expressed and form heterotetramers (GIRK1/GIRK2, GIRK1/GIRK3, GIRK2/GIRK3) and homotetramers (GIRK2/GIRK2) in various brain regions (A). Addictive substances or neurotransmitters bind to GPCRs, and the GIRK channel is activated by the G protein \( G_{\beta\gamma} \) subunit. Following this activation, potassium ions (\( K^+ \)) flow into the cell, and cellular excitability decreases (B).

GIRK2 subunits can uniquely form functional homomers in the brain [4]. These various compositions exhibit \( K^+ \) selectivity, inward rectification, and G-protein-dependent gating [2,4]. Outward \( K^+ \) currents through GIRK channels inhibit cellular excitability [2,4]. The core reward circuitry in the brain consists of the VTA, nucleus accumbens (NAc), and ventral pallidum via the medial forebrain bundle. The VTA is the initiating nucleus of the dopaminergic system, which then projects to the NAc via the medial forebrain bundle [9]. Dopamine neurons in the VTA also project to the amygdala, orbitofrontal cortex, anterior cingulate cortex, hippocampus, and prefrontal cortex [10]. Dopamine neurons in the VTA express only the GIRK2 and GIRK3 subunits, whereas \( \gamma \)-aminobutyric acid (GABA) neurons in the VTA express the GIRK1, GIRK2, and GIRK3 subunits [5,6]. Addictive substances enhance reward circuitry in the brain and produce feelings of pleasure. These “rewarding effects” positively reinforce their use and increase relapse risk. Addictive substances include alcohol, nicotine, caffeine, psychostimulants (amphetamines, methamphetamine), cocaine, and opioids [11]. Activation by these substances is mediated by interactions with G-protein-coupled receptors (GPCRs), including GABA receptors, N-methyl-D-aspartate (NMDA) receptors, nicotinic acetylcholine receptors, adenosine receptors, and opioid receptors, as well as dopamine transporters [10,12–19]. Following the stimulation of GPCRs, GIRK channels are activated through coupling of the \( G_{i/o} \) family of G-proteins to those receptors and gated by G-protein \( \beta\gamma \) subunits that are released from the G-protein \( \alpha \) subunit [20,21] (Figure 1B). G-protein \( \beta\gamma \) subunits activate GIRK channels through direct binding with
amino- and carboxyl-ends of the channels [2,22]. The G-protein α subunit was not thought to be responsible for GIRK channel activation, but rather to be a regulator of the specificity of channel activation [4,23]. Among addictive substances, alcohol activates GIRK channels in a G-protein-independent manner [24], whereas cocaine and phencyclidine directly inhibit GIRK channels at toxic concentrations [25,26]. Early studies in mice that lacked GIRK channel subunits suggested that GIRK channels play an important role in regulating behavioral effects of addictive substances (Table 1).

Table 1. GIRK channel genes manipulations and substance-related behaviors.

| Gene | Genetic Modification | Drug       | Result                                      | Reference                          |
|------|----------------------|------------|---------------------------------------------|-----------------------------------|
| Girl1| KO                   | Cocaine    | ↓ Motor activity                             | Arora et al., 2010 [27]           |
|      |                      | Morphine   | ↓ Antinociceptive effects                    | Marker et al., 2004 [28]          |
|      |                      | Morphine   | ↓ Motor activity                             | Kozell et al., 2009 [7]           |
|      |                      | Morphine   | ↓ Motor activity                             | Kotecki et al., 2015 [29]         |
| Girl2| KO                   | Cocaine    | ↓ Self-administration                        | Morgan et al., 2003 [30]          |
|      |                      | Cocaine    | ↓ Motor activity                             | Arora et al., 2010 [27]           |
|      |                      | Alcohol    | ↓ Conditioned place preference/Conditioned   | Hill et al., 2003 [31]            |
|      |                      | Morphine   | ↓ Motor activity                             | Kotecki et al., 2015 [29]         |
|      |                      | Morphine   | ↓ Antinociceptive effects                    | Marker et al., 2004 [28]          |
| 1B   | Missense mutation    | Alcohol    | ↓ Antinociceptive effects                    | Kobayashi et al., 1999 [24]       |
|      |                      | Opioids    | ↓ Antinociceptive effects                    | Ikeda et al., 2000 [32]           |
|      |                      | Amphetamine| ↓ Motor activity                             | Schmidt et al., 1982 [33]         |
|      |                      | Methamphetamine | ↓ Conditioned place preference | Ikekubo et al., 2020 [34]         |
| 1A   | KO in DA neurons     | Cocaine    | ↑ Behavioral sensitivity                      | McCall et al., 2017 [35]          |
| 1C   | Overexpression in DA | Cocaine    | ↓ Motor activity                             | McCall et al., 2019 [36]          |
| 1D   | KO                   | Cocaine    | ↓ Self-administration                        | Morgan et al., 2003 [30]          |
|      |                      | Morphine   | ↓ Motor activity                             | Kotecki et al., 2015 [29]         |
|      |                      | Alcohol    | ↓ Withdrawal                                 | Kozell et al., 2009 [7]           |
|      |                      | Alcohol    | ↓ Conditioned place preference               | Tipps et al., 2016 [37]           |
|      |                      | Alcohol    | ↓ Binge-like drinking                        | Herman et al., 2015 [38]          |
| 3    | Overexpression in DA | Cocaine    | ↓ Motor activity                             | McCall et al., 2019 [36]          |

KO: Knock out, DA: dopamine. Up arrow: Increased behavioral phenotype, Down arrow: Decreased/inhibited behavioral phenotype.

GIRK1 knockout and GIRK2 knockout mice exhibited baseline hyperactivity and an increase in locomotor response to cocaine [27]. GIRK1 knockout and GIRK2 knockout mice exhibited a decrease in analgesic responses after morphine administration into the spinal cord [28]. GIRK2 knockout and GIRK3 knockout mice also exhibited a decrease in cocaine self-administration [30]. GIRK2 knockout mice did not exhibit alcohol-induced conditioned taste aversion or conditioned place preference [31]. Morphine-induced activity increased in GIRK1 knockout and GIRK2 knockout mice but decreased in GIRK3 knockout mice compared with wildtype mice [29]. GIRK3 knockout mice exhibited a reduction of alcohol withdrawal [7] and an alcohol-induced conditioned place preference [37]. Additionally, GIRK3 knockout mice exhibited a selective increase in alcohol binge-like drinking without affecting alcohol metabolism or the sensitivity to alcohol intoxication [38]. The roles of GIRK channels have also been studied using weaver mutant mice, which have spontaneously occurring autosomal recessive mutations of the GIRK2 gene that lead to a reduction of GIRK2 channel function and cause abnormalities of dopamine signaling [39]. Weaver mutant mice exhibited lower antinociceptive effects of alcohol [24] and opioids [32]. Amphetamine
caused less hyperlocomotion in weaver mutant mice [33]. Weaver mutant mice also did not exhibit methamphetamine-induced conditioned place preference or priming effects [34]. A significant decrease in basal and methamphetamine-induced dopamine release was also detected in the NAc, with a decrease in methamphetamine-induced neural activity in the posterior NAc shell [34]. Furthermore, neuron-specific knockout mice have been generated to investigate the role of GIRK channels in the reward system. McCall et al. (2017) reported that the genetic ablation of GIRK2 in dopamine neurons, which did not alter the baseline excitability of VTA dopamine neurons, increased behavioral sensitivity to cocaine [35]. The overexpression of GIRK3 in VTA dopamine neurons decreased GABA_B receptor- and dopamine D2 receptor-dependent signaling and increased cocaine-induced locomotion, whereas the overexpression of GIRK2 increased GABA_B receptor-dependent signaling and decreased cocaine-induced locomotion [36]. Knockout and missense mutation mice are useful for studying the response of GIRK channels to addictive substances, but the response to addictive substances may differ between mice with knockouts and missense mutations. This may be attributable to the complete or functional deficiency of GIRK channels. The relevance of GIRK channel function in VTA dopamine neurons has been demonstrated, and GIRK channels have been shown to play a key role in behavioral responses to addictive substances. In human studies, Nishizawa et al. reported associations between GIRK channels and addictive substances by analyzing single-nucleotide polymorphisms (SNPs). Human gene polymorphism analysis revealed that the rs2835859 SNP in the KCNJ6 gene, which encodes the GIRK2 subunit, was associated with nicotine dependence [40]. Single-nucleotide polymorphisms at A1032G in the KCNJ6 gene were reported to be associated with sensitivity to opioids after major abdominal surgery [41]. These previous animal and human studies indicate that GIRK channels shape many behavioral responses to addictive substances, suggesting that medications that target GIRK channels may be useful for treating patients with SUDs.

3. Pharmacological Modulation of GIRK Channels and Therapeutic Effects

Although GIRK channels are activated in a G-protein-dependent or -independent manner by addictive substances, antipsychotic compounds, psychoactive compounds (e.g., antidepressants, including selective serotonin re-uptake inhibitors), and a cerebral circulation/metabolism ameliorator were shown to block brain-type GIRK1/GIRK2 channels and cardiac-type GIRK1/GIRK4 channels in the Xenopus oocyte expression assay [42–47]. Interestingly, fluoxetine, desipramine, paroxetine, sertraline, and ifenprodil blocked alcohol-induced GIRK1/GIRK2 currents [43–47]. Ifenprodil can also inhibit GIRK channels at a lower IC50 than antidepressants (e.g., fluoxetine, imipramine, desipramine, amitriptyline, nortriptyline, clomipramine, maprotiline, paroxetine, sertraline, duloxetine, and amoxapine) [43–47]. Each GIRK channel was inhibited by ifenprodil at the following IC50 values: 7.01 ± 0.92 µM at GIRK1/GIRK2, 8.76 ± 1.26 µM at GIRK2, and 2.83 ± 0.69 µM at GIRK1/GIRK4 [46]. Although these compounds do not have specificity for GIRK channels, some of these compounds were shown to inhibit behaviors that are induced by addictive substances. Takamatsu et al. reported that pretreatment with fluoxetine and paroxetine inhibited methamphetamine-induced conditioned place preference in mice, which was unaffected by fluvoxamine, an antidepressant that does not block GIRK channels [48,49]. However, paroxetine has several adverse effects, including serotonin syndrome, neuropathic malignant syndrome, convulsions, toxic epidermal necrosis, anti-diuretic hormone incompatible secretion syndrome, severe liver dysfunction, rhabdomyolysis, low white blood cell counts, and anaphylaxis [50]. The U.S. Food and Drug Administration (FDA) approved fluoxetine, but it is not currently approved for use in Japan. Ifenprodil is a blocker of α1-adrenergic receptors, GluN2B subunit-containing NMDA receptors [51,52], and sigma-1/2 receptors [53], and also inhibits GIRK channels [46,51]. Ifenprodil inhibited methamphetamine-induced conditioned place preference [34], and pretreatment with ifenprodil reduced morphine-induced conditioned place preference in mice [55]. Ifenprodil also inhibited the amphetamine-induced potentiation of excitatory postsynaptic currents in rat
midbrain dopamine neurons [56]. Pretreatment with a combination of ifenprodil and cyproheptadine in mice did not cause locomotor sensitization compared with mice that were pretreated with saline when the mice were repeatedly injected with D-amphetamine [57]. Notably, ifenprodil inhibits GluN2B subunit-containing NMDA receptors at a lower IC\textsubscript{50} than GIRK channels (IC\textsubscript{50}: 0.34 μM at GluN1A/GluN2B receptors; see IC\textsubscript{50} values for GIRK channels above) [51]. A recent study reported that the methamphetamine-induced increase in locomotor activity (i.e., behavioral sensitization) was blocked by ifenprodil via GluN2B-protein phosphatase 2A-AKT signaling in the dorsal striatum in mice [58]. These studies suggest that ifenprodil inhibits behaviors that are induced by addictive substances through GluN2B subunit-containing NMDA receptors. Thus, ifenprodil may exert effects on behaviors that are caused by addictive substances through NMDA receptors and/or GIRK channels. Kotechi et al. reported that GIRK2/GIRK3 channels in VTA dopamine neurons regulated morphine-induced motor activity, whereas GIRK channel activation in VTA GABA neurons was not required [29]. GIRK channels play a key role in the influence of addictive substances on the reward system, but further studies are warranted to define the mechanisms of action of ifenprodil.

Ifenprodil has been used as a treatment for dizziness after brain ischemia (<60 mg/day) in a few countries, including Japan and France. A high dose of ifenprodil (60–300 mg/kg, the mechanisms of action of ifenprodil.

Table 2. Clinical studies of GIRK channel inhibitors in SUDs.

| Treatment                        | Study Design                        | Drug            | Result                                                                 | Reference         |
|----------------------------------|-------------------------------------|-----------------|----------------------------------------------------------------------|-------------------|
| Ifenprodil                       | Case report *                       | Alcohol         | ↓ Pain in the extremities and headache 
↓ Tremors in the fingers | Goto, 2010 [61]     |
| Ifenprodil, Paroxetine, and Haloperidol | Retrospective chart review **      | Alcohol         | ↓ The lack of negative expectancy for drinking on the SRRS          | Ogai et al., 2011 [62] |
| Ifenprodil, Paroxetine, and Sertraline | Retrospective chart review **      | Alcohol         | ↓ The positive expectancy for alcohol on the SRRS                  | Sugaya et al., 2012 [63] |
| Ifenprodil                       | Randomized, controlled, rater-blinded study | Alcohol         | ↓ Alcohol use scores                                                 | Sugaya et al., 2018 [64] |
| Ifenprodil                       | Randomized, double-blind, exploratory, dose-ranging, placebo-controlled study | Methamphetamine | ↓ The days of methamphetamine use during the follow-up period       | Kotajima-Murakami et al., 2022 [65] |
| Ifenprodil                       | Case report *                       | Alcohol, Bron   | ↓ Craving                                                          | Hori et al., 2010 [66] |

*: Abstract of Japanese conference; **: reports in Japanese academic journals; SRRS: Stimulant Relapse Risk Scale. Down arrow: Decreased the effects of addictive substances.

Goto reported that ifenprodil diminished pain in the extremities, headache, and tremors in the fingers in patients with alcohol use disorder [61]. In a retrospective chart review of patients with alcohol use disorder, patients who took GIRK channel inhibitors, including ifenprodil, were compared to patients who did not take GIRK channel inhibitors [62,63]. These studies showed that GIRK channel inhibition improved the lack of negative expectancy for drinking and the positive expectancy for alcohol, which are components of relapse risk on the Stimulant Relapse Risk Scale (SRRS), in outpatients and inpatients [62,63]. These results suggest that ifenprodil may benefit from a redesign as a therapeutic agent for patients with SUDs. We conducted two clinical trials to investigate...
the effects of ifenprodil in patients with SUDs in Japan. In the first clinical trial, patients with alcohol use disorder were examined. The study had a randomized, controlled, rater-blinded, single-center design, and the drug administration period was 3 months [64]. This study found that ifenprodil (60 mg/day) administration for 3 months improved alcohol use scores in patients with alcohol use disorder (Figure 2), and no patients reported adverse events from ifenprodil [64].

Alcohol use total score was calculated using the following formula:

\[ \text{Score} = \frac{1}{2} \times \left( \text{frequency of alcohol drinking} \times 5 + \text{the presence of heavy drinking} \times 1 \right) \]

![Figure 2](image-url)  
**Figure 2.** Effects of ifenprodil treatment on alcohol use scores. Weighted mean of the frequency of alcohol drinking and the presence or absence of heavy drinking were calculated as the alcohol use total score. The frequency of alcohol drinking was assessed by asking the following question: “How often did you use alcohol for the past month?” Respondents answered by selecting one of six choices (0 = none, 1 = once per month, 2 = two to four times per month, 3 = two or three times per week, 4 = four to six times per week, and 5 = every day). The presence or absence of heavy drinking was assessed by asking the following question: “Have you drunk heavily for the past month?” Respondents answered “Yes” or “No” (1 = Yes, 0 = No). The difference in alcohol use scores at time 2 (after 3 months) was calculated after adjusting the score at baseline (time 1). The number of participants was the following: ifenprodil (n = 25), control (n = 21). The data were analyzed using analysis of covariance. Error bars indicate standard deviations. The figure was modified from Sugaya et al., 2018 [64]. Reprinted/adapted with permission from Ref. [64]. Copyright year; 2018, copyright owner’s name; Kazutaka Ikeda.

In the second clinical trial, the effects of ifenprodil were examined in patients with methamphetamine use disorder [65,67]. Methamphetamine is one of the most abused drugs in Japan [68]. This study was conducted in Japan and had a randomized, double-blind, exploratory, dose-ranging, placebo-controlled, single-center design. Three arms (placebo, 60 mg/day ifenprodil, and 120 mg/day ifenprodil groups), including high-dose ifenprodil, were set in the study because 120 mg/day ifenprodil suppressed craving without adverse events in a patient who was addicted to various substances (Bron®, cough medicine, and alcohol) [66]. The administration period was 84 days (12 weeks), with the following numbers of participants: placebo group (n = 10), 60 mg/day ifenprodil group (n = 11), and 120 mg/day ifenprodil group (n = 11). The primary outcome was the use or nonuse of methamphetamine during the drug administration period in the placebo group vs. the 120 mg/day ifenprodil group (see our previous studies for secondary outcomes).
In this clinical trial, we did not find effects of ifenprodil on the primary or secondary outcomes [65,67]. The additional analyses, however, showed that the number of days of methamphetamine use during the follow-up period was lower, and emotional problems on the SRRS improved after treatment with 120 mg/day ifenprodil compared with both the placebo and 60 mg/day ifenprodil groups [65,67]. Importantly, there were no adverse events associated with ifenprodil or placebo administration. However, these two clinical trials had a common limitation—that is, a relatively low number of patients. Future clinical trials should include larger samples to assess more precisely the efficacy of ifenprodil treatment. Our studies were the first clinical trials on the treatment of SUDs (alcohol and methamphetamine) with ifenprodil, demonstrating the safety of ifenprodil in patients with SUDs. Further clinical studies should evaluate ifenprodil as a pharmacotherapy for SUDs. Recent studies reported a new class of subunit-selective GIRK channel modulators (GIRK1-containing or non-GIRK1-containing GIRK channels) [69]. ML297 (VU0456810) selectively activates GIRK1-containing heteromers and prevents epilepsy [70]. V0529331 is a synthetic small molecule that was reported to activate non-GIRK1-containing GIRK channels. The discovery of this molecule may be useful for developing selective non-GIRK1-containing GIRK channel probes [71]. Crystal structures of the GIRK2 channel and G-protein βγ subunit were analyzed [72]. In 2019, potassium channel tetramerization domain-containing protein, a modifited subunit of the GABA_b receptor, was shown to modulate the kinetics of GIRK channels, resulting in rapid desensitization [73]. These studies could be useful for identifying the role of GIRK channel subunits and for developing medications that are specific to GIRK2/GIRK3 channels in VTA dopamine neurons, which are at the hub of reward circuitry in the brain.

4. Future Directions

Substance use disorders are chronic diseases. Patients with SUDs and associated societal problems exist worldwide, including in Japan [1]. The FDA has approved several medications for the treatment of alcohol and opioid use disorders in combination with counseling and behavioral therapies [74]. Acamprosate, disulfiram, and naltrexone are used for alcohol use disorder. Buprenorphine, methadone, naltrexone, and naloxone are used for opioid use disorder. No medications have yet been approved for methamphetamine use disorder. The development of new medications and availability of more treatment options would undoubtedly be beneficial for patients with SUDs. The present review focused on SUDs, but addiction can occur beyond SUDs, such as behavioral addictions [75]. Although the objects on which individuals depend are different, the reward system in the brain plays key roles in both SUDs and behavioral addictions [76]. Future studies should test the efficacy of ifenprodil and other medications for the treatment of behavioral addictions.

5. Concluding Remarks

GIRK channels are essential mediators of cellular excitability in the central nervous system and are involved in the rewarding effects of addictive substances. Previous studies with GIRK channel knockout and mutant mice confirmed that GIRK channels are involved in regulating behavioral responses to addictive substances. Our two clinical trials suggest that ifenprodil might be effective for patients with alcohol use disorder and methamphetamine use disorder, without causing severe adverse events. Ifenprodil is not a selective GIRK channel blocker; it also inhibits α1-adrenergic receptors, GluN2B-containing NMDA receptors, and sigma-1/2 receptors. Future studies should clarify the mechanisms by which ifenprodil acts to treat SUDs. Understanding the molecular and structural bases by which addictive drugs act on GIRK channels and how they change their gating and conformation properties will provide new insights into the development of novel treatments for SUDs.

**Author Contributions:** Conceptualization, H.K.-M. and K.I.; investigation, H.K.-M., S.I. and K.I.; visualization, H.K.-M.; writing—original draft preparation, H.K.-M. and S.I.; writing—review and editing, S.I. and K.I. All authors have read and agreed to the published version of the manuscript.
**Funding:** This study was supported by the Japan Agency for Medical Research and Development (AMED, no. JP18dk0307071) and Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, KAKENHI (JP22H04922 [AdAMS], 22K07340, and 21K06814).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We thank Michael Arends for proofreading the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

SUD Substance use disorder  
GIRK G-protein-activated inwardly rectifying potassium  
VTA Ventral tegmental area  
NAc Nucleus accumbens  
GPCR G-protein-coupled receptor  
NMDA N-methyl-D-aspartate  
GABA γ-aminobutyric acid  
SNP Single-nucleotide polymorphism  
SRRS Stimulant Relapse Risk Scale

**References**

1. Office on Drugs and Crime. World Drug Report 2021. Available online: https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html (accessed on 25 August 2022).
2. Hibino, H.; Inanobe, A.; Furutani, K.; Murakami, S.; Findlay, I.; Kurachi, Y. Inwardly Rectifying Potassium Channels: Their Structure, Function, and Physiological Roles. *Physiol. Rev.* 2010, 90, 291–366. [CrossRef] [PubMed]
3. Kubo, Y.; Reuveny, E.; Slesinger, P.A.; Jan, Y.N.; Jan, L.Y. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. *Nature* 1993, 364, 802–806. [CrossRef]  
4. Lüscher, C.; Slesinger, P.A. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. *Nat. Rev. Neurosci.* 2010, 11, 301–315. [CrossRef] [PubMed]
5. Karschin, C.; Dissmann, E.; Stuhmer, W.; Karschin, A. IRK(1-3) and GIRK(1-4) inwardly rectifying K+ channel mRNAs are differentially expressed in the adult rat brain. *J. Neurosci.* 1996, 16, 3559–3570. [CrossRef]  
6. Kobayashi, T.; Ikeda, K.; Ichikawa, T.; Abe, S.; Togashi, S.; Kumanishi, T. Molecular Cloning of a Mouse G-Protein-Activated K+ Channel (mGIRK1) and Distinct Distributions of 3 GIRK (GIRK1, 2 and 3) mRNAs in Mouse Brain. *Biochem. Biophys. Res. Commun.* 1995, 208, 1166–1173. [CrossRef]  
7. Kozell, L.B.; Walter, N.A.R.; Milner, L.C.; Wickman, K.; Buck, K.J. Mapping a Barbiturate Withdrawal Locus to a 0.44 Mb Interval and Analysis of a Novel Null Mutant Identify a Role for Kcnj9 (GIRK3) in Withdrawal from Pentobarbital, Zolpidem, and Ethanol. *J. Neurosci.* 2009, 29, 11662–11673. [CrossRef]  
8. Wickman, K.; Karschin, C.; Karschin, A.; Picciotto, M.R.; Clapham, D.E. Brain Localization and Behavioral Impact of the G-Protein-Gated K+ Channel Subunit GIRK. *J. Neurosci.* 2000, 20, 5608–5615. [CrossRef]  
9. Poisson, C.L.; Engel, L.; Saunders, B.T. Dopamine Circuit Mechanisms of Addiction-Like Behaviors. *Front. Neural Circuits* 2021, 15, 752420. [CrossRef]  
10. Van Huijstee, A.N.; Mansvelder, H.D. Glutamatergic synaptic plasticity in the mesocorticolimbic system in addiction. *Front. Cell. Neurosci.* 2014, 8, 466. [CrossRef]  
11. Sugaya, N.; Kobayashi, T.; Ikeda, K.; Nagisa, S.; Toru, K.; Kazutaka, I. Role of GIRK Channels in Addictive Substance Effects. *J. Drug Alcohol Res.* 2013, 2, 238825. [CrossRef]  
12. Andrade, R.; Malenka, R.C.; Nicoll, R.A. A G Protein Couples Serotonin and GABA B Receptors to the Same Channels in Hippocampus. *Science* 1986, 234, 1261–1265. [CrossRef] [PubMed]  
13. Cruz, H.G.; Ivanova, T.; Lunn, M.-L.; Stoffel, M.; Slesinger, P.A.; Luescher, C. Bi-directional effects of GABAB receptor agonists on the mesolimbic dopamine system. *Nat. Neurosci.* 2004, 7, 153–159. [CrossRef] [PubMed]  
14. Egan, T.M.; North, R.A. Acetylcholine hyperpolarizes central neurones by acting on an M2 muscarinic receptor. *Nature* 1986, 319, 405–407. [CrossRef] [PubMed]  
15. Gu, Y.-Z.; Schonbrunn, A. Coupling Specificity between Somatostatin Receptor sst2A and G Proteins: Isolation of the Receptor-G Protein Complex with a Receptor Antibody. *Mol. Endocrinol.* 1997, 11, 527–537. [CrossRef]
42. Kobayashi, T.; Ikeda, K.; Kumanishi, T. Inhibition of various antipsychotic drugs of the G-protein-activated inwardly rectifying K+ (GIRK) channels expressed in Xenopus oocytes. J. Cereb. Blood Flow Metab. 2000, 129, 1716–1722. [CrossRef]

43. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac). J. Cereb. Blood Flow Metab. 2003, 138, 1119–1128. [CrossRef]

44. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of GIRK channel by fluoxetine. J. Pharm. Sci. 2006, 102, 278–287. [CrossRef]

45. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of GIRK channel by the antidepressant fluoxetine. J. Pharm. Sci. 2006, 31, 516–524. [CrossRef]

46. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine. J. Pharm. Sci. 2010, 62, 129, 1116–1126. [CrossRef]

47. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine. J. Cereb. Blood Flow Metab. 2000, 129, 1716–1722. [CrossRef]

48. Takamatsu, Y.; Yamamoto, H.; Higino, Y.; Markou, A.; Ikeda, K. The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice. Curr. Neuropharmacol. 2011, 9, 68–72. [CrossRef]

49. Takamatsu, Y.; Yamamoto, H.; Ogai, Y.; Higino, Y.; Markou, A.; Ikeda, K. Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur. J. Neurosci. 2005, 22, 1476–1488. [CrossRef]

50. Miyatake, M.; Narita, M.; Shibasaki, M.; Nakamura, A.; Suzuki, T. Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur. J. Neurosci. 2005, 22, 1476–1488. [CrossRef]

51. Li, M.-H.; Underhill, S.M.; Reed, C.; Phillips, T.J.; Amara, S.; Ingram, S.L. Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology 2017, 42, 1539–1547. [CrossRef]

52. Trovero, F.; David, S.; Bernard, P.; Puech, A.; Bizot, J.-C.; Tassin, J.-P. The Combination of Marketed Antagonists of NMDA Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence. PLoS ONE 2016, 11, e0151242. [CrossRef]

53. Mony, L.; Kew, J.N.C.; Gunthorpe, M.J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. J. Cereb. Blood Flow Metab. 2009, 157, 1301–1317. [CrossRef]

54. Miyatake, M.; Narita, M.; Shibasaki, M.; Nakamura, A.; Suzuki, T. Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur. J. Neurosci. 2005, 22, 1476–1488. [CrossRef]

55. Li, M.-H.; Underhill, S.M.; Reed, C.; Phillips, T.J.; Amara, S.; Ingram, S.L. Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology 2017, 42, 1539–1547. [CrossRef]

56. Trovero, F.; David, S.; Bernard, P.; Puech, A.; Bizot, J.-C.; Tassin, J.-P. The Combination of Marketed Antagonists of NMDA Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence. PLoS ONE 2016, 11, e0151242. [CrossRef]

57. Mony, L.; Kew, J.N.C.; Gunthorpe, M.J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. J. Cereb. Blood Flow Metab. 2009, 157, 1301–1317. [CrossRef]

58. Miyatake, M.; Narita, M.; Shibasaki, M.; Nakamura, A.; Suzuki, T. Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur. J. Neurosci. 2005, 22, 1476–1488. [CrossRef]

59. Li, M.-H.; Underhill, S.M.; Reed, C.; Phillips, T.J.; Amara, S.; Ingram, S.L. Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology 2017, 42, 1539–1547. [CrossRef]

60. Trovero, F.; David, S.; Bernard, P.; Puech, A.; Bizot, J.-C.; Tassin, J.-P. The Combination of Marketed Antagonists of NMDA Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence. PLoS ONE 2016, 11, e0151242. [CrossRef]

61. Mony, L.; Kew, J.N.C.; Gunthorpe, M.J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. J. Cereb. Blood Flow Metab. 2009, 157, 1301–1317. [CrossRef]

62. Miyatake, M.; Narita, M.; Shibasaki, M.; Nakamura, A.; Suzuki, T. Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur. J. Neurosci. 2005, 22, 1476–1488. [CrossRef]

63. Li, M.-H.; Underhill, S.M.; Reed, C.; Phillips, T.J.; Amara, S.; Ingram, S.L. Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology 2017, 42, 1539–1547. [CrossRef]

64. Trovero, F.; David, S.; Bernard, P.; Puech, A.; Bizot, J.-C.; Tassin, J.-P. The Combination of Marketed Antagonists of NMDA Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence. PLoS ONE 2016, 11, e0151242. [CrossRef]

65. Mony, L.; Kew, J.N.C.; Gunthorpe, M.J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. J. Cereb. Blood Flow Metab. 2009, 157, 1301–1317. [CrossRef]

66. Miyatake, M.; Narita, M.; Shibasaki, M.; Nakamura, A.; Suzuki, T. Glutamatergic neurotransmission and protein kinase C play a role in neuron-glia communication during the development of methamphetamine-induced psychological dependence. Eur. J. Neurosci. 2005, 22, 1476–1488. [CrossRef]

67. Li, M.-H.; Underhill, S.M.; Reed, C.; Phillips, T.J.; Amara, S.; Ingram, S.L. Amphetamine and Methamphetamine Increase NMDAR-GluN2B Synaptic Currents in Midbrain Dopamine Neurons. Neuropsychopharmacology 2017, 42, 1539–1547. [CrossRef]
68. Matsumoto, T.; Usami, T.; Yamamoto, T.; Funada, D.; Murakami, M.; Okita, K.; Shimane, T. Impact of COVID-19-related stress on methamphetamine users in Japan. *Psychiatry Clin. Neurosci.* 2021, 75, 236–238. [CrossRef]

69. Weaver, C.D.; Denton, J.S. Next-generation inward rectifier potassium channel modulators: Discovery and molecular pharmacology. *Am. J. Physiol. Physiol.* 2021, 320, C1125–C1140. [CrossRef]

70. Kaufmann, K.; Romaine, I.; Days, E.; Pascual, C.; Malik, A.; Yang, L.; Zou, B.; Du, Y.; Sliwoski, G.; Morrison, R.D.; et al. ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice. *ACS Chem. Neurosci.* 2013, 4, 1278–1286. [CrossRef] [PubMed]

71. Kozek, K.A.; Du, Y.; Sharma, S.; Prael, F.J., 3rd; Spitznagel, B.D.; Kharade, S.V.; Denton, J.S.; Hopkins, C.R.; Weaver, C.D. Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels. *ACS Chem. Neurosci.* 2019, 10, 358–370. [CrossRef] [PubMed]

72. Whorton, M.R.; MacKinnon, R. X-ray structure of the mammalian GIRK2-beta-gamma G-protein complex. *Nature* 2013, 498, 190–197. [CrossRef] [PubMed]

73. Zheng, S.; Abreu, N.; Levitz, J.; Kruse, A.C. Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. *Nature* 2019, 567, 127–131. [CrossRef] [PubMed]

74. SAMHSA. Medication-Assisted Treatment (MAT). Available online: https://www.samhsa.gov/medication-assisted-treatment (accessed on 11 August 2022).

75. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed.; American Psychiatric Publishing: Washington, DC, USA, 2013; pp. 561–570.

76. Blum, K.; Badgaiyan, R.D. Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. *EC Psychol. Psychiatr.* 2021, 10, 1–4. [PubMed]